Video
Biomarker Assay as Alternative to Early-Stage Prostate Cancer Detection
Author(s):
Jake Micallef, PhD, chief scientific officer, VolitionRX, discusses a study that examined the efficacy of the NuQ biomarker assay as a detection tool for early-stage prostate cancer.
Jake Micallef, PhD, chief scientific officer, VolitionRX, discusses a study that examined the efficacy of the NuQ biomarker assay as a detection tool for early-stage prostate cancer.
In the retrospective study, researchers collected blood samples of 537 men—half of whom had prostate cancer. The NuQ test is described as 93% cancer-specific, Micallef explains, adding that this is a higher specificity than prostate-specific antigen (PSA) screening.
Additionally, the test was found to detect more than 70% of early-stage prostate cancers and 86% of late-stage disease.
